Interestingly, up-regulation of the microglial glucagon-like peptide-1 receptor (GLP-1R) was identified as a disease marker in Parkinson’s disease and targeting of GLP-1R with an agonist lead to its down-regulation and the abolishment of microglia-dependent A1 astrocyte conversion [63]. The gene discussed is GLP1R; the disease is Parkinson disease.